Additional file 4 of Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors

Additional file 4: Table S3. Associations of extent of synergy with THZ531 and molecular weight, pheophorbide A accumulation and ABCG2 activity model predictions. Only kinase inhibitors with >40% remaining proliferation upon individual kinase inhibitor treatment are shown. NA values for pheophorbide A results include kinase inhibitors not available in updated libraryor outliers. Kinase inhibitors with NA values for ABCG2 activity predictions were not evaluated